This study is testing if adding a drug called Durvalumab to chemotherapy can help treat high-grade upper urinary tract cancer better than chemotherapy alone. Durvalumab is an immunotherapy, which means it helps your immune system fight cancer. Chemotherapy is a treatment that uses drugs to stop cancer cells from growing, dividing, or spreading. Researchers want to see if using both treatments before surgery might shrink the tumor more effectively than using only chemotherapy.

• The study lasts up to 5 years with regular follow-ups, but the initial treatment phase lasts for up to 4 cycles (each cycle is either 14 or 21 days).
• Participants may receive either chemotherapy alone or chemotherapy combined with Durvalumab, depending on their eligibility for certain drugs.
• Risks include typical side effects from chemotherapy and immunotherapy, such as fatigue, nausea, or low blood counts.

To join, participants must be 18 or older, have a specific type of urinary tract cancer, and meet other health criteria. Those with certain infections, recent surgeries, or specific health conditions might not be eligible. This study involves intravenous treatments, biopsies, and imaging tests like CT or MRI scans.